A unifying trend across recent Alzheimer's Disease (AD) literature is the convergence of multiple regulated cell-death pathways—ferroptosis, cuproptosis, and apoptosis-adjacent mechanisms—onto shared upstream failures in proteostasis and organelle quality control. Ferroptosis, driven by iron loading and lipid peroxidation, and cuproptosis, driven by copper binding to lipid-acetylated mitochondrial proteins and loss of Fe-S cluster proteins, both converge on mitochondrial dysfunction as a proximate trigger for neuronal death. This reframes AD not as a single-lesion disease but as a multi-pathway degenerative cascade in which metal dyshomeostasis (copper, iron), oxidative lipid damage, and defective mitochondrial clearance reinforce one another in a vicious cycle involving neurodegeneration, synaptic impairment, and vascular contributions.
Centrally linking these death pathways is a breakdown in autophagy-mitophagy machinery. ULK1 downregulation, impaired lysosomal acidification, defective SNARE-mediated autophagosome-lysosome fusion, and accumulation of damaged organelles collectively describe a system in which cells lose the capacity to clear misfolded proteins (amyloid-β, tau) and dysfunctional mitochondria. This clearance failure sits mechanistically upstream of both classical protein aggregation and newer cell-death paradigms, positioning autophagy/mitophagy restoration—rather than amyloid clearance alone—as a therapeutic node. Compounds like curcumin, explored for effects on ferroptosis, autophagy, and liquid-liquid phase separation of amyloid-β, exemplify a shift toward multi-target natural and small-molecule agents that address several of these mechanisms simultaneously.
A second major thread is the immune-brain axis, encompassing microglia, astrocytes, peripheral T lymphocytes, and systemic aging processes such as T cell immunosenescence. Emerging interventions—mTOR inhibition, PD-1/PD-L1 blockade, and mesenchymal stromal cell therapy—originally developed for organismal/immune aging are being repositioned toward brain aging and neurodegeneration, reflecting a broader trend of treating AD as a manifestation of systemic immunosenescence and chronic neuroinflammation (pro-inflammatory cytokines from reactive astrocytes and over-activated microglia) rather than a brain-confined pathology. This is paralleled by interest in cell therapy and mesenchymal approaches explicitly framed as superior to "existing approaches" because they may halt neurodegenerative processes and promote nervous tissue regeneration, rather than merely slowing symptomatic decline.
Finally, the field shows growing attention to sex-specific disease burden (women comprising two-thirds of AD cases), peripheral and accessible biomarkers (fibroblast-based senescence markers, blood-based indicators), and non-canonical infectious/systemic contributors (Long COVID, SARS-CoV-2-induced Golgi fragmentation and endomembrane disruption, HIV-1-altered glutamate biosynthesis). Together these strands suggest a macro trend toward integrative, mechanism-stacked models of AD that unite metal-dependent cell death, autophagic/mitophagic failure, systemic immune aging, and viral/environmental triggers—driving therapeutic strategies that combine small-molecule modulators (ferroptosis/cuproptosis inhibitors, curcumin), immunomodulatory biologics (PD-1 blockade, mTOR inhibitors), and regenerative cell therapies.